Lexaria Preparing For Strategic Growth
Lexaria Preparing For Strategic Growth
Strategic growth plan execution underway.
战略增长计划正在实施。
KELOWNA, BC / ACCESSWIRE / July 16, 2024 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces plans for strategic growth.
BC省KELOWNA / ACCESSWIRE / 2024年7月16日 / 全球药物递送平台创新者Lexaria Bioscience Corp.(纳斯达克股票代码:LEXX)(纳斯达克股票代码:LEXXW)(下称“公司”或“Lexaria”)宣布战略增长计划。
"Lexaria has certain initiatives underway that are increasing confidence in our medium-term and longer-term strategies," said Chris Bunka, Chief Executive Officer of Lexaria Bioscience Corp. "As a result of the success we are experiencing and the continued success we are anticipating, we will be implementing a number of strategic steps in the weeks and months to come."
“Lexaria正在推进某些倡议,增强了我们中期和长期战略的信心,”Lexaria Bioscience Corp.的首席执行官Chris Bunka说。“由于我们正经历的成功以及我们预计的持续成功,我们将在未来数周和数月内实施一系列战略步骤。”
Lexaria will be expanding its management team this summer as it prepares for the greater workload of multiple projects and initiatives. The first step is appointing Nelson Cabatuan as our consulting Chief Strategic Financial Advisor, in order to maximize his skills in the fields of corporate finance and strategic industry relationships and opportunities. Nelson is resigning from his current role as Chief Financial Officer (CFO) in order to better focus on the strategic opportunities afforded to the Company outside of typical accounting tasks. Our new CFO will be appointed and announced in due course.
Lexaria将在今年夏天扩大其管理团队,以便为多个项目和倡议的更大工作量做好准备。第一步是任命Nelson Cabatuan为我们的咨询首席战略金融顾问,以最大限度地发挥他在企业金融和战略行业关系与机遇方面的技能。Nelson将辞去他目前的首席财务官(CFO)职务,并在公司常规会计任务之外更好地专注于公司的战略机遇。我们的新CFO将在适当的时候被任命并宣布。
The Company is also in the conceptual design stages of additional R&D projects related to additional GLP-1 molecules of interest, beyond those previously disclosed. Announcements about additional R&D studies may be made over the next several months. Finally, Lexaria is closely examining its Phase 1b hypertension study, that has already received clearance to proceed from the FDA, for more concrete steps to launch that study, subject to funding, as soon as possible.
该公司还处于与其他GLP-1分子有关的附加研发项目的概念设计阶段,超越了之前披露的范围。有关其他研发研究的公告可能会在接下来的几个月内发布。最后,Lexaria正在密切审查其已从FDA获得批准继续进行的10亿高血压研究,以便更具体地采取推出该研究的行动,是否有资金支持尽快启动。
About Lexaria Bioscience Corp. & DehydraTECH
关于Lexaria Bioscience Corp.和DehydraTECH
DehydraTECH is Lexaria's patented drug delivery formulation and processing platform technology which improves the way active pharmaceutical ingredients (APIs) enter the bloodstream through oral delivery. Since 2016, Lexaria has developed and investigated DehydraTECH with a variety of beneficial molecules in oral and topical formats. DehydraTECH has repeatedly demonstrated the ability to increase bio-absorption and has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier, which Lexaria believes to be of particular importance for centrally active compounds. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 46 patents granted and many patents pending worldwide. For more information, please visit .
DehydraTECH是Lexaria专有的药物递送配方及处理平台技术,通过口服途径改善了活性药物成分(APIs)进入血液的方式。自2016年以来,Lexaria已经开发和研究了DehydraTECH,并尝试将其应用在口服和局部使用中的多种有益分子中。DehydraTECH已经反复证明了其增强吸收率的功能,并且还证明了一些药物穿过血脑屏障的能力,Lexaria认为这对于对中枢活性化合物特别重要。Lexaria在业内拥有一个许可证的内部研究实验室,并拥有一份完整的专利组合,其中46项获得授权的专利和许多在全球尚待获得授权。欲了解更多信息,请访问公司网站。
CAUTION REGARDING FORWARD-LOOKING STATEMENTS
关于前瞻性声明的警告
This press release includes forward-looking statements. Statements as such term is defined under applicable securities laws. These statements may be identified by words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions. Such forward-looking statements in this press release include, but are not limited to, statements by the company relating the Company's ability to carry out research initiatives, receive regulatory approvals or grants or experience positive effects or results from any research or study. Such forward-looking statements are estimates reflecting the Company's best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that the Company will actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements. As such, you should not place undue reliance on these forward-looking statements. Factors which could cause actual results to differ materially from those estimated by the Company include, but are not limited to, government regulation and regulatory approvals, managing and maintaining growth, the effect of adverse publicity, litigation, competition, scientific discovery, the patent application and approval process, potential adverse effects arising from the testing or use of products utilizing the DehydraTECH technology, the Company's ability to maintain existing collaborations and realize the benefits thereof, delays or cancellations of planned R&D that could occur related to pandemics or for other reasons, and other factors which may be identified from time to time in the Company's public announcements and periodic filings with the US Securities and Exchange Commission on EDGAR. The Company provides links to third-party websites only as a courtesy to readers and disclaims any responsibility for the thoroughness, accuracy or timeliness of information at third-party websites. There is no assurance that any of Lexaria's postulated uses, benefits, or advantages for the patented and patent-pending technology will in fact be realized in any manner or in any part. No statement herein has been evaluated by the Food and Drug Administration (FDA). Lexaria-associated products are not intended to diagnose, treat, cure or prevent any disease. Any forward-looking statements contained in this release speak only as of the date hereof, and the Company expressly disclaims any obligation to update any forward-looking statements or links to third-party websites contained herein, whether as a result of any new information, future events, changed circumstances or otherwise, except as otherwise required by law.
本新闻稿包括前瞻性声明。此类术语根据适用证券法的定义。这些陈述可以从公司透露的计划、意图或期望中识别出来。本新闻稿中的此类前瞻性陈述包括本公司与公司相关的能够开展研究计划、获得监管批准或资助、或从任何研究或研究获得积极影响或结果与之相关的用语。这样的前瞻性陈述是基于目前信息进行的估计,涉及许多风险和不确定性,并且不能保证公司实际上将实现在这些前瞻性声明中披露的计划、意图或期望。因此,您不应过度依赖这些前瞻性陈述。可能导致公司的实际结果与根据对此类陈述的实质的最佳判断所进行的估计有所不同的因素包括,但不限于,政府监管和监管批准、管理和维护增长、恶意宣传的影响、诉讼、竞争、科学发现、专利申请和批准过程、可能源于使用利用DehydraTECH技术的产品所导致的潜在负面影响、公司的能力以维护现有的合作关系并实现其益处、计划中的研究和开发可能由于流行病或其他原因而发生延迟或取消,以及公司在公告和在EDGAR向美国证券交易委员会进行的定期提交中不时发现的其他因素。公司仅将第三方网站链接提供给读者,仅作为一种礼貌行为,并否认对第三方网站信息的全面性、准确性或实时性的任何责任。Lexaria所推测的技术的任何用途、好处或优势都不能保证在任何程度或任何方面得以实现。本文中的任何语句均未获得食品和药物管理局(FDA)的评估。Lexaria相关的产品不旨在诊断、治疗、治愈或预防任何疾病。本发布中包含的任何前瞻性陈述仅当作本条款发布的日期说起,公司明确否认对这些前瞻性陈述或本发布包含的第三方网站链接进行任何更新的义务,无论是出于任何新信息、未来事件、变化的情况或其他原因,除非法律另有规定。
INVESTOR CONTACT:
投资者联系方式:
George Jurcic - Head of Investor Relations
ir@lexariabioscience.com
Phone: 250-765-6424, ext 202
George Jurcic—投资者关系负责人
ir@lexariabioscience.com
电话: +1-250-765-6424, 分机202
SOURCE: Lexaria Bioscience Corp.
来源:Lexaria Bioscience Corp.